Views of competition take center stage in US FTC, Edwards-JenaValve trial day two
Perceptions of the future for aortic regurgitation heart valve devices were front and center Wednesday as a trial between the US Federal Trade Commission and Edwards Lifesciences’ acquisition of JenaValve continued. Larry...To view the full article, register now.
Already a subscriber? Click here to view full article